Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer.

Authors: Faghih, Z  Erfani, N  Razmkhah, M  Sameni, S  Talei, A  Ghaderi, A 
Citation: Faghih Z, etal., Mol Biol Rep. 2009 Sep;36(7):1923-8. doi: 10.1007/s11033-008-9400-7. Epub 2008 Nov 7.
Pubmed: (View Article at PubMed) PMID:18989750
DOI: Full-text: DOI:10.1007/s11033-008-9400-7

Interleukin-13 (IL-13) is a TH2 cytokine with direct and indirect immunoregulatory functions on cancer cells. The cytokine has been reported to have some polymorphic variations at the gene level associated with some immune related diseases including asthma and allergy. In the present study, association of three IL13 gene polymorphisms at positions -1512 A/C and -1055 C/T in the promoter and +2044 G/A in exon-4 was investigated in Iranian women with breast cancer and healthy controls. Genotyping of IL13 gene polymorphisms were performed by PCR-RFLP methods. Serum level of IL-13 was assessed by ELISA. Haplotypes were constructed from genotypic data using Arlequin 3.1 software package. Haplotype analysis revealed higher frequency of a three-locus haplotype, ACA (-1512A/-1055C/+2044A), in normal women than breast cancer patients (P < 0.025). Haplotype CCA, from the other hand, was observed with more frequency among patients than controls (P < 0.03). No statistically significant differences were found in the frequency of genotypes and alleles between patients and control group. No association was observed between investigated genotypes and other prognostic factors including tumor type, lymph node involvement and tumor size. IL-13 serum level was undetectable in both patients and control subjects. Despite observing no association between breast cancer and the single SNPs, results of this investigation suggest that the presence of CCA haplotype of IL13 gene may be associated with susceptibility of Iranian women to breast cancer.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 8549503
Created: 2014-03-27
Species: All species
Last Modified: 2014-03-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.